Press release
Anaplastic Thyroid Cancer Pipeline 2025: Groundbreaking Clinical Advancements by 8+ Global Leaders - DelveInsight | Featuring Takeda, Shanghai Henlius Biotech, Taizhou Hanzhong Pharmaceuticals, AffyImmune Therapeutics, Inc., Merck & Co, Iovance Biotherape
Anaplastic Thyroid Cancer Pipeline 2025, DelveInsight
DelveInsight's "Anaplastic Thyroid Cancer Pipeline Insight 2025" report provides a detailed and strategic evaluation of the ongoing R&D landscape. It covers clinical trial progression, emerging therapies, mechanisms of action, competitive positioning, and key company initiatives. The report serves as a crucial resource for stakeholders-including researchers, healthcare investors, and decision-makers, seeking insights into the evolving Anaplastic Thyroid Cancer Therapeutics Market and the breakthroughs shaping its future trajectory.
Explore the Cutting-Edge Landscape of Anaplastic Thyroid Cancer Drug Development @ https://www.delveinsight.com/report-store/anaplastic-thyroid-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr
Key Takeaways from the Anaplastic Thyroid Cancer Pipeline Report
DelveInsight's Anaplastic Thyroid Cancer pipeline report depicts a robust space with 8+ active players working to develop 8+ pipeline therapies for Anaplastic Thyroid Cancer treatment.
In August 2024, the FDA granted Regenerative Medicine Advanced Therapy (RMAT) designation to AIC100, an investigational CAR T-cell therapy targeting ICAM-1, for the treatment of recurrent ATC.
Key Anaplastic Thyroid Cancer companies such as Takeda, Shanghai Henlius Biotech, Taizhou Hanzhong Pharmaceuticals, AffyImmune Therapeutics, Inc., Merck & Co, Iovance Biotherapeutics, Inc., Codiak BioSciences, Hutchison Medipharma Limited, Bristol-Myers Squibb, and others are evaluating new drugs for Anaplastic Thyroid Cancer to improve the treatment landscape.
Promising Anaplastic Thyroid Cancer pipeline therapies in various stages of development include Sapanisertib, HLX208, and others.
Anaplastic Thyroid Cancer Overview:
Anaplastic thyroid cancer (ATC) is a rare and aggressive form of thyroid cancer. The thyroid is a hormone-producing gland located at the front of the neck, just below the Adam's apple. Unlike other thyroid cancers, ATC spreads rapidly to other parts of the body. It primarily affects individuals over the age of 60 and is also known as anaplastic thyroid carcinoma. Although uncommon, ATC accounts for only 1% to 2% of all thyroid cancer cases, with an estimated one to two diagnoses per million people each year in the United States. The disease may begin as a lump in the neck, and as the tumor grows, it can press on the vocal cords, causing hoarseness, or obstruct the windpipe, making it hard to breathe. In some cases, ATC can go unnoticed for a time if the tumor remains small.
Download the Anaplastic Thyroid Cancer sample report to know in detail about the Anaplastic Thyroid Cancer treatment market @ https://www.delveinsight.com/sample-request/anaplastic-thyroid-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr
Anaplastic Thyroid Cancer Pipeline Analysis
The Anaplastic Thyroid Cancer pipeline insights report 2025, provides insights into:
Provides comprehensive insights into key companies developing therapies in the Anaplastic Thyroid Cancer Market.
Categorizes Anaplastic Thyroid Cancer therapeutic companies by development stage: early, mid, and late-stage.
Highlights major companies involved in targeted therapy development, including both active and inactive (paused/discontinued) projects.
Reviews emerging Anaplastic Thyroid Cancer drugs under development based on:
Stage of development
Anaplastic Thyroid Cancer Route of administration
Target receptor
Monotherapy vs. combination therapy
Anaplastic Thyroid Cancer Mechanism of action
Molecular type
Offers detailed analysis of:
Company-to-company and company-academia collaborations
Anaplastic Thyroid Cancer Licensing agreements
Funding and investment activities supporting future Anaplastic Thyroid Cancer market advancement.
Unlock key insights into emerging Anaplastic Thyroid Cancer therapies and market strategies here: https://www.delveinsight.com/report-store/anaplastic-thyroid-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr
Anaplastic Thyroid Cancer Emerging Drugs
Sapanisertib - Takeda
Sapanisertib is a dual inhibitor of TORC1 and TORC2, designed to disrupt a crucial survival pathway in tumor cells with KEAP1/NRF2 mutations. These genetic alterations are common in a significant portion of patients with various solid tumors. The drug has shown encouraging results as a standalone treatment in patients with relapsed or treatment-resistant NRF2-mutated squamous non-small cell lung cancer (NSCLC). In preclinical models, sapanisertib demonstrated distinct anti-cancer activity compared to TORC1-targeting rapalogs in NRF2-mutated squamous NSCLC.
HLX208 - Shanghai Henlius Biotech
HLX208 is a small-molecule inhibitor targeting the BRAF V600E mutation, which may be applicable in treating a range of solid tumors. The drug has the potential to be used in combination with Henlius's proprietary antibodies targeting EGFR or PD-1, aiming to build a robust, innovative, and differentiated oncology portfolio for various cancer indications.
Anaplastic Thyroid Cancer Pipeline Therapeutic Assessment
Anaplastic Thyroid Cancer Assessment by Product Type
• Mono
• Combination
• Mono/Combination
Anaplastic Thyroid Cancer By Stage
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
Anaplastic Thyroid Cancer Assessment by Route of Administration
• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical
Anaplastic Thyroid Cancer Assessment by Molecule Type
• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy
Download sample pages to get an in-depth assessment of the emerging Anaplastic Thyroid Cancer therapies and key Anaplastic Thyroid Cancer companies: https://www.delveinsight.com/sample-request/anaplastic-thyroid-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr
Table of Contents
1. Report Introduction
2. Executive Summary
3. Anaplastic Thyroid Cancer Current Treatment Patterns
8. Anaplastic Thyroid Cancer - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
8. Anaplastic Thyroid Cancer Late-Stage Products (Phase-III)
7. Anaplastic Thyroid Cancer Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
8. Inactive Products
11. Dormant Products
12. Anaplastic Thyroid Cancer Discontinued Products
13. Anaplastic Thyroid Cancer Product Profiles
18. Anaplastic Thyroid Cancer Key Companies
15. Anaplastic Thyroid Cancer Key Products
18. Dormant and Discontinued Products
17. Anaplastic Thyroid Cancer Unmet Needs
18. Anaplastic Thyroid Cancer Future Perspectives
19. Anaplastic Thyroid Cancer Analyst Review
20. Appendix
21. Report Methodology
Request the sample PDF to get detailed insights about the Anaplastic Thyroid Cancer pipeline reports offerings: https://www.delveinsight.com/report-store/anaplastic-thyroid-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr
Contact Info:
Kritika Rehani
Assistant Manager, Marketing & Branding
krehani@delveinsight.com
info@delveinsight.com
+14699457679
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Anaplastic Thyroid Cancer Pipeline 2025: Groundbreaking Clinical Advancements by 8+ Global Leaders - DelveInsight | Featuring Takeda, Shanghai Henlius Biotech, Taizhou Hanzhong Pharmaceuticals, AffyImmune Therapeutics, Inc., Merck & Co, Iovance Biotherape here
News-ID: 4050088 • Views: …
More Releases from DelveInsight Business Research LLP
Genital Warts Pipeline Insights Report 2025 | DelveInsight
DelveInsight's, "Genital Warts Pipeline Insight 2025" report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in Genital Warts pipeline landscape. It covers the Genital Warts pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore the comprehensive insights by DelveInsight and stay ahead…
Traumatic Brain Injury Pipeline Drugs Report 2025 | DelveInsight
DelveInsight's "Traumatic Brain Injury Pipeline Insight 2025" report provides comprehensive insights about 20+ companies and 22+ pipeline drugs in Tthe raumatic Brain Injury pipeline landscape. It covers the Traumatic Brain Injury pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Traumatic Brain Injury pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore…
Bone Metastasis Pipeline Assessment Report 2025 | DelveInsight
DelveInsight's, "Bone Metastases Pipeline Insight, 2025," report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Bone Metastases pipeline landscape. It covers the Bone Metastasis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Bone Metastasis pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore the comprehensive insights by DelveInsight…
Acquired Immunodeficiency Syndrome Treatment Market Size Report 2032 | DelveInsi …
DelveInsight's "Acquired Immunodeficiency Syndrome Market Insights, Epidemiology, and Market Forecast-2032′′ report offers an in-depth understanding of the Acquired Immunodeficiency Syndrome, historical and forecasted epidemiology as well as the Acquired Immunodeficiency Syndrome market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
To Know in detail about the Acquired Immunodeficiency Syndrome market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Acquired Immunodeficiency Syndrome Market…
More Releases for Anaplastic
Anaplastic Astrocytoma Market Outlook, Epidemiology, Landscape and Growth Trajec …
Anaplastic astrocytoma (AA) is a rare, malignant brain tumor classified as World Health Organization (WHO) Grade III glioma, characterized by its aggressive nature and poor prognosis. While not as common as glioblastoma, anaplastic astrocytoma represents a significant challenge due to its high recurrence rates, limited treatment options, and resistance to conventional therapies.
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/70897
Over the past decade, the treatment landscape has slowly evolved…
Anaplastic Large Cell Lymphoma Drugs Market: An In-Depth Analysis
The global Anaplastic Large Cell Lymphoma Drugs market was valued approximately USD 10.5 billion in 2022 and is projected to reach around USD 17.1 billion by 2032, exhibiting a compound annual growth rate (CAGR) of 5% during the forecast period.
Anaplastic Large Cell Lymphoma Drugs Market Overview
Anaplastic Large Cell Lymphoma is a rare type of non-Hodgkin lymphoma characterized by the proliferation of large lymphoid cells. The market for ALCL…
Anaplastic Astrocytoma Market Development, Trends, Segmentations Analysis
Anaplastic astrocytoma is a very rare type of malignant brain tumor affecting human at all ages. As this tumor develops from astrocytes, the star-shaped brain cells it is termed as astrocytoma. The astrocytes along with other cells protect nerve cells in the brain and spinal cord by surrounding them. All these protective cells are collectively termed as glial cells. World Health Organization (WHO) graded these tumors on a scale from…
Anaplastic Astrocytoma - Pipeline Review, H2 2017 - Pharmaceutical Report
Anaplastic astrocytoma is a grade III tumor. It accounts for two percent of all brain tumors. It is a type of glioma that develops from star-shaped glial cells (astrocytes), which support nerve cells. Anaplastic astrocytoma grows faster and more aggressively than grade II astrocytomas. The tumor cells are not uniform in appearance and invade neighboring tissue. Symptoms include headache, weakness, clumsiness, difficulty walking and seizures. Anaplastic astrocytoma is common among…
Anaplastic Oligoastrocytoma Market Snapshot by 2024 – Persistence Market Resea …
Oligoastrocytomas is a part of a group of brain tumor called “gliomas”. Glioma tumor is originated in the brain or spine. Oligoastrocytomas contains both astrocytoma cells and oligodendroglioma. About 2.3% of the brain tumors reported are diagnosed as oligoastrocytomas. Oligoastrocytomas is divided into two parts, low grade and anaplastic. According to the WHO grading system, anaplastic oligoastrocytomas are usually identify as grade 1 and grade 2 but sometimes they appear…
Latest Report Details Of Global Anaplastic Thyroid Cancer Market
Marketresearchreports.biz has added a new research report on the "Anaplastic Thyroid Cancer-Pipeline Insights, 2017" to its collection.
DelveInsights, Anaplastic Thyroid Cancer- Pipeline Insights, 2017, report provides in depth insights on the pipeline drugs and their development activities around the Anaplastic Thyroid Cancer. The DelveInsightsReport covers the product profiles in various stages of development including Discovery, Pre-clinical, IND, Phase I, Phase II, Phase III and Preregistration. Report covers the product clinical…
